New research pits psychedelic-assisted therapy against traditional antidepressants in an unblinded study that presents a sobering viewpoint on the treatment's potential.

Background At least 60% of stroke, 40% of dementia and 35% of late-life depression (LLD) are attributable to modifiable risk factors, with great overlap due to shared pathophysiology. This study aims ...

A new study found that people with depression and anxiety who used GLP-1 drugs like Ozempic and Wegovy had a 42% lower risk ...

A Lancet Psychiatry study found no evidence cannabinoids treat anxiety, PTSD. In NY, any practitioner can certify a patient ...

Sea buckthorn berries are nutrient-dense fruits rich in antioxidants, vitamins, and bioactive compounds with potential ...

Javascript must be enabled to use this site. Please enable Javascript in your browser and try again. A Passion for Issues that Matter to Americans 50-Plus is All You ...

GLP-1 medications like semaglutide (Ozempic) may offer unexpected mental health benefits alongside weight loss. A large study ...

Her research work is conducted within the NIHR Cambridge Biomedical Research Centre (BRC) Mental Health and Neurodegeneration Themes. She receives Royalties from Cambridge University Press for Brain ...

The largest review of medicinal cannabis to date found it doesn’t effectively treat anxiety, depression, or PTSD—despite ...

This phenomenon can distort the results of psychedelic drug trials. While a placebo in a traditional antidepressant drug ...

Using medical or recreational marijuana to ease symptoms of numerous mental health conditions doesn’t work, according to new analyses ...

Over the years these pages and many others have reported on the risks of using ayahuasca and kambo, psychoactive substances used by shamans, alt-med practitioners, cranks and downright frauds for ...